Interim results from a Phase II trial: axitinib + Gemzar median OS 6.9 months vs 5.6 months for single-agent Gemzar - a 26% reduction in the risk of death. In a subset of 94 patients with a good performance status, the combination reduced the risk of death by 33%
Word on the street is that axitinib is about to move into Phase III in pancreatic cancer - in 2H 2007
